Table 2.
Randomized Clinical Trials evaluating the optimal dosage of thromboprophylaxis in hospitalized patients with COVID-19.
| Study | N | ICU (%) | Comparator | Intervention | Result-Conclusion |
|---|---|---|---|---|---|
| X-COVID-19 [44] | 183 | 0 | Prophylactic Enoxaparin |
Intermediate Enoxaparin |
Underpowered Fewer pulmonary embolism events with Intermediate |
| HEP-COVID [37] | 253 | 33 | Prophylactic or Intermediate LMWH/UFH |
Therapeutic Enoxaparin |
Improved clinical outcomes with Therapeutic only in non-ICU patients |
| RAPID [38] | 465 | 0 | Prophylactic LMWH/UFH |
Therapeutic LMWH/UFH |
Fewer deaths with Therapeutic |
| Perepu et al. [43] | 176 | 62 | Prophylactic Enoxaparin |
Intermediate Enoxaparin |
No difference |
| ACTION [24] | 615 | 6 | Prophylactic Enoxaparin/UFH (mainly Enoxaparin) |
Extended Therapeutic Rivaroxaban /Enoxaparin/UFH (mainly Rivaroxaban) |
No difference |
| INSPIRATION [32] | 562 | 100 | Prophylactic Enoxaparin |
Intermediate Enoxaparin |
No difference |
| HESACOVID [39] | 20 | 100 | Prophylactic Enoxaparin/UFH | Therapeutic Enoxaparin |
Improved oxygenation parameters with Therapeutic |
| Oliynyk et al. [40] | 126 | 100 | Prophylactic Enoxaparin |
Therapeutic Enoxaparin/UFH |
Improved clinical outcomes with Therapeutic |
| REMAP-CAP, ACTIV-4a and ATTACC Critically ill [36] |
1098 | 100 | Prophylactic or Intermediate LMWH/UFH |
Therapeutic LMWH/UFH |
No difference |
| REMAP-CAP, ACTIV-4a and ATTACC Non-critically ill [35] |
2219 | 0 | Prophylactic or Intermediate LMWH/UFH |
Therapeutic LMWH/UFH |
Improved clinical outcomes with Therapeutic |
| COVID-HEP [41] | 159 | 28 | Prophylactic (acutely) or Intermediate (critically) enoxaparin/UFH |
Therapeutic enoxaparin/UFH |
No difference |
| BEMICOP [42] | 65 | 0 | Prophylactic Bemiparin |
Therapeutic Bemiparin |
No difference |
ICU, intensive care unit; LMWH; Low molecular weight heparin; UFH, Unfractionated heparin.